Preferential use of dexamethasone for fetal lung maturation in severe coronavirus disease 2019

Dellapiana, Gabriela; Naqvi, Mariam; Leggett, Cecilia B.; Tholemeier, Lauren N.; Burwick, Richard M.

doi:10.1016/j.ajogmf.2020.100218

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methylprednisolone pulse therapy (125 mg per day for three days) was added to suppress a COVID-19-invoked cytokine storm in the maternal body. On the other hand, prolonged administration of corticosteroids is not recommended because of possible adverse effects on the fetus, such as the development of fetal adrenal insufficiency and impaired childhood neurodevelopment [ 10 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

High-Dose Corticosteroids for a Pregnant Woman Critically Ill With Coronavirus Disease 2019

Yamamoto¹,

Hagiya²,

Maki³

et al. 2021

Cureus

View full text Add to dashboard Cite

Pregnancy was reported to be a risk factor for coronavirus disease 2019 (COVID-19), with an increased risk for premature birth. Corticosteroids and remdesivir are used for patients with COVID-19; however, there is no established treatment for these patients. In particular, the effective management of pregnant, critically ill patients with COVID-19 remains unknown. We describe a 34-year-old, critically ill woman at 30 weeks of gestation with COVID-19, who was successfully treated with remdesivir and combined high-dose betamethasone (12 mg/day for two days) and methylprednisolone (125 mg/day for three days) followed by steroid tapering. During treatment, fetal biophysical profile scores on obstetric ultrasound were normal; her pregnancy course progressed well. Since high-dose corticosteroids improve fetal lung maturation and as well as cytokine storm due to COVID-19, this case provides an insight into the management of pregnant COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

High-Dose Corticosteroids for a Pregnant Woman Critically Ill With Coronavirus Disease 2019

Yamamoto¹,

Hagiya²,

Maki³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…Fortunately, only a low proportion of infected individuals develop mild or severe diseases that required hospitalization and admittance to an intensive care unit, but still, given the magnitude of the pandemic, imply a collapse in countries with limited resources and facilities. During 2020, no effective treatments and vaccines were available, only non-pharmacological interventions (NPI), including the massive use of face masks (including personal protection equipments [PPE], such as N95 filters, especially for healthcare workers), and after December 2021, some treatments, including the use dexamethasone [34][35][36][37][38], and RNA and viral vector vaccines, such as BNT162b2 vaccine (Pfizer/BioNTech®), the ChAdOx1 nCoV-19 vaccine (AstraZeneca/Oxford®), mRNA-1273 (Moderna®), among others, were available and widely used [39][40][41][42][43][44][45].…”

Section: Introductionmentioning

confidence: 99%

Introductory Chapter: Lessons from SARS-CoV-2/COVID-19 after Two Years of Pandemic

Rodríguez‐Morales¹,

Bonilla-Aldana²

2023

Infectious Diseases

View full text Add to dashboard Cite

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Rabaan

Al-Ahmed

Sah

et al. 2020

Ann Clin Microbiol Antimicrob

107

View full text Add to dashboard Cite

A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.

show abstract

Preferential use of dexamethasone for fetal lung maturation in severe coronavirus disease 2019

Cited by 3 publications

References 7 publications

High-Dose Corticosteroids for a Pregnant Woman Critically Ill With Coronavirus Disease 2019

High-Dose Corticosteroids for a Pregnant Woman Critically Ill With Coronavirus Disease 2019

Introductory Chapter: Lessons from SARS-CoV-2/COVID-19 after Two Years of Pandemic

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Contact Info

Product

Resources

About